HRP20120526T1 - Radiofarmaceutski pripravci koji sadrže polisaharide vezane na poliamine - Google Patents
Radiofarmaceutski pripravci koji sadrže polisaharide vezane na poliamine Download PDFInfo
- Publication number
- HRP20120526T1 HRP20120526T1 HRP20120526AT HRP20120526T HRP20120526T1 HR P20120526 T1 HRP20120526 T1 HR P20120526T1 HR P20120526A T HRP20120526A T HR P20120526AT HR P20120526 T HRP20120526 T HR P20120526T HR P20120526 T1 HRP20120526 T1 HR P20120526T1
- Authority
- HR
- Croatia
- Prior art keywords
- polysaccharide
- preparation
- bringing
- contact
- polyvalent metal
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract 21
- 229920001282 polysaccharide Polymers 0.000 title claims abstract 21
- 239000005017 polysaccharide Substances 0.000 title claims abstract 21
- 239000000203 mixture Substances 0.000 title claims abstract 3
- 229920000768 polyamine Polymers 0.000 title 1
- 229940121896 radiopharmaceutical Drugs 0.000 title 1
- 239000012217 radiopharmaceutical Substances 0.000 title 1
- 230000002799 radiopharmaceutical effect Effects 0.000 title 1
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims abstract 12
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims abstract 12
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims abstract 12
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims abstract 10
- 230000000536 complexating effect Effects 0.000 claims abstract 9
- 229910052751 metal Inorganic materials 0.000 claims abstract 9
- 239000002184 metal Substances 0.000 claims abstract 9
- 239000005700 Putrescine Substances 0.000 claims abstract 6
- 229940063673 spermidine Drugs 0.000 claims abstract 6
- 229940063675 spermine Drugs 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 239000003638 chemical reducing agent Substances 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 239000007800 oxidant agent Substances 0.000 claims abstract 3
- 230000003647 oxidation Effects 0.000 claims abstract 3
- 238000007254 oxidation reaction Methods 0.000 claims abstract 3
- 230000001590 oxidative effect Effects 0.000 claims abstract 3
- 238000012800 visualization Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 229910052718 tin Inorganic materials 0.000 claims 2
- 229920000936 Agarose Polymers 0.000 claims 1
- 229920000945 Amylopectin Polymers 0.000 claims 1
- 229920000856 Amylose Polymers 0.000 claims 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims 1
- 229910052765 Lutetium Inorganic materials 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 229910052772 Samarium Inorganic materials 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 229910052733 gallium Inorganic materials 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims 1
- 238000011271 lymphoscintigraphy Methods 0.000 claims 1
- 230000002906 microbiologic effect Effects 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229910052702 rhenium Inorganic materials 0.000 claims 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims 1
- 229910052706 scandium Inorganic materials 0.000 claims 1
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 229910052712 strontium Inorganic materials 0.000 claims 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052713 technetium Inorganic materials 0.000 claims 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Postupak priprave pripravka koji sadrži polisaharid koji sadrži jednu ili više kompleksirajućih skupina koje se dobiva kovalentnim vezanjem putrescina NH CH NH spermina H N CH NH CH NH CH NH spermidina NH CH NH CH NH ili kadaverina NH CH NH s navedenim polisaharidom gdje sveili neke od navedenih kompleksirajućih skupina tvore kompleks s najmanje jednim polivalentnim metalom naznačen time što se navedeni postupak sastojiu koracima i dovođenja polisaharida u kontakt soksidansom za kontroliranu oksidaciju ii dovođenja oksidiranog polisaharida u kontakt s kompleksirajući spoj kojeg se bira između putrescina spermina spermidina ili kadaverina iii izborno u dovođenju polisaharida dobivenog u koraku ii u kontakt s reducensom iiv dovođenju polisaharida dobivenog u koraku ii ili koraku iii u kontakt sa solju polivalentnog metala gdje je sol polivalentnogmetala mTc Patent sadrži još patentnih zahtjeva
Claims (15)
1. Postupak priprave pripravka koji sadrži polisaharid koji sadrži jednu ili više kompleksirajućih skupina koje se dobiva kovalentnim vezanjem putrescina NH2(CH2)4NH2, spermina H2N(CH2)3NH(CH2)4NH(CH2)3NH2, spermidina NH2(CH2)3NH(CH2)4NH2 ili kadaverina NH2(CH2)5NH2 s navedenim polisaharidom, gdje sve ili neke od navedenih kompleksirajućih skupina tvore kompleks s najmanje jednim polivalentnim metalom,
naznačen time što se navedeni postupak sastoji u koracima:
i) dovođenja polisaharida u kontakt s oksidansom za kontroliranu oksidaciju;
ii) dovođenja oksidiranog polisaharida u kontakt s kompleksirajući spoj kojeg se bira između putrescina, spermina, spermidina ili kadaverina;
iii) izborno u dovođenju polisaharida dobivenog u koraku ii) u kontakt s reducensom; i
iv) dovođenju polisaharida dobivenog u koraku ii) ili koraku iii) u kontakt sa solju polivalentnog metala,
gdje je sol polivalentnog metala 99mTc.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se korak iv) provodi u prisutnosti reducensa tipa kositra, borata i njegovih derivata ili tipa askorbinske kiseline.
3. Pripravak koji sadrži polisaharid koji sadrži jednu ili više kompleksirajućih skupina koje se dobiva kovalentnim vezanjem putrescina NH2(CH2)4NH2, spermina H2N(CH2)3NH(CH2)4NH(CH2)3NH2, spermidina NH2(CH2)3NH(CH2)4NH2 ili kadaverina NH2(CH2)5NH2 s navedenim polisaharidom, gdje sve ili neke od navedenih kompleksirajućih skupina tvore kompleks s najmanje jednim polivalentnim metalom,
gdje je polisaharid biljnog ili mikrobiološkog podrijetla i bira se između škroba, celuloze, amilopektina, amiloze, agaroze, kitozana, pululana ili dekstrana, te smjesa od dva ili više njih, naznačen time što se navedeni pripravak može pripraviti postupkom koji se sastoji u koracima:
i) dovođenja polisaharida u kontakt s oksidansom za kontroliranu oksidaciju;
ii) dovođenja oksidiranog polisaharida u kontakt s kompleksirajući spoj kojeg se bira između putrescina, spermina, spermidina ili kadaverina;
iii) izborno u dovođenju polisaharida dobivenog u koraku ii) u kontakt s reducensom; i
iv) dovođenju polisaharida dobivenog u koraku ii) ili koraku iii) u kontakt sa solju polivalentnog metala,
gdje se polivalentni metal bira između radioaktivnih izotopa tehnecija, renija, bakra, stroncija, indija, samarija, kositra, skandija, itrija, galija, gadolinija ili lutecija, od kojih je osobito poželjan 99mTc.
4. Pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polisaharid u obliku čestica.
5. Pripravak u skladu s patentnim zahtjevom 4, naznačen time što je veličina čestica između 10 nm i 200 µm.
6. Pripravak u skladu s bilo kojim od patentnih zahtjeva 3 do 5, naznačen time što dodatno sadrži farmaceutski prihvatljivu pomoćnu tvar.
7. Diagnostički ili farmaceutski pripravak za ljudsku ili životinjsku farmakopeju, naznačen time što sadrži pripravak u skladu s patentnim zahtjevima 3 do 6.
8. Upotreba pripravka u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačena time što je namijenjena pripravi dijagnostičkog pripravka za medicinsku ili veterinarsku vizualizaciju.
9. Upotreba u skladu s patentnim zahtjevom 8, naznačena time što je namijenjena scintigrafskoj vizualizaciji.
10. Upotreba pripravka u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačena time što je namijenjena pripravi dijagnostičkog pripravka za scintigrafsko dijagnosticiranje plućne embolije.
11. Upotreba u skladu s patentnim zahtjevom 9, naznačena time što je namijenjena detekciji stražarskih čvorova ili limfoscintigrafiji.
12. Upotreba pripravka u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačena time što je navedeni pripravak namijenjen vizualizaciji jednog ili više organa kod pacijenta ili životinje uz pomoć medicinske vizualizacije.
13. Upotreba u skladu s patentnim zahtjevom 12, naznačena time što su promatrani organi pluća, jetra, slezena, koštana srž ili limfni čvorovi.
14. Upotreba pripravka u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačena time što je namijenjena proizvodnji farmaceutskog pripravka za liječenje raka kod pacijenta ili životinje uz pomoć interne radioterapije.
15. Upotreba u skladu s patentnim zahtjevom 14, naznačena time što rak čine tumori limfnih čvorova ili jetre ili slezene.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95209407P | 2007-07-26 | 2007-07-26 | |
| FR0756750A FR2919189A1 (fr) | 2007-07-26 | 2007-07-26 | Nouvelles compositions a base de polyosides greffes par des composes polyamines ou polysoufres. |
| PCT/EP2008/059825 WO2009013358A2 (en) | 2007-07-26 | 2008-07-25 | New compositions based on polysaccharides grafted by polyamine or polysulphurised compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120526T1 true HRP20120526T1 (hr) | 2012-07-31 |
Family
ID=38896852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120526AT HRP20120526T1 (hr) | 2007-07-26 | 2012-06-21 | Radiofarmaceutski pripravci koji sadrže polisaharide vezane na poliamine |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9023396B2 (hr) |
| EP (1) | EP2175888B1 (hr) |
| JP (1) | JP5946241B2 (hr) |
| KR (1) | KR101562817B1 (hr) |
| CN (1) | CN101861171B (hr) |
| AU (1) | AU2008278976B2 (hr) |
| BR (1) | BRPI0814470B1 (hr) |
| CA (1) | CA2694582C (hr) |
| CY (1) | CY1113022T1 (hr) |
| DK (1) | DK2175888T3 (hr) |
| ES (1) | ES2386849T3 (hr) |
| FR (1) | FR2919189A1 (hr) |
| HK (1) | HK1149211A1 (hr) |
| HR (1) | HRP20120526T1 (hr) |
| IL (1) | IL203512A (hr) |
| MX (1) | MX2010001013A (hr) |
| PL (1) | PL2175888T3 (hr) |
| PT (1) | PT2175888E (hr) |
| RS (1) | RS52405B (hr) |
| RU (1) | RU2481856C2 (hr) |
| SI (1) | SI2175888T1 (hr) |
| WO (1) | WO2009013358A2 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101664444B1 (ko) * | 2013-12-13 | 2016-10-12 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | 생분해성 의료용 접착제 또는 실란트 조성물 |
| RU2570114C1 (ru) * | 2014-09-17 | 2015-12-10 | Федеральное государственное бюджетное учреждение науки Институт высокомолекулярных соединений Российской академии наук | Способ получения водорастворимых полимерных комплексов радиоизотопов |
| ES2846848T3 (es) | 2015-10-26 | 2021-07-29 | Harvard College | Polisacáridos reducidos y oxidados y métodos de uso de los mismos |
| PL240772B1 (pl) * | 2018-06-11 | 2022-06-06 | Nanothea Spolka Akcyjna | Sposób wytwarzania nanocząstek polimerowych chelatujących izotopy promieniotwórcze do zastosowania w diagnostyce i terapii |
| CN108785323B (zh) * | 2018-06-26 | 2020-09-18 | 中国医学科学院基础医学研究所 | 作为免疫增强剂的精胺修饰的普鲁兰多糖 |
| CN115490774A (zh) * | 2022-08-16 | 2022-12-20 | 湖北第二师范学院 | 一种精胺修饰羟乙基直链淀粉基因转染材料及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7412164L (sv) * | 1974-09-27 | 1976-03-29 | Pharmacia Ab | Medel for intravaskuler administrering |
| SE9803482D0 (sv) * | 1998-10-13 | 1998-10-13 | Anders Holmberg | Ion exchange tumor targeting (IETT) |
| FR2797769B1 (fr) * | 1999-09-01 | 2003-07-25 | Cis Bio Int | Produits radiopharmaceutiques et leur procede de preparation |
| US6756363B1 (en) * | 2000-11-17 | 2004-06-29 | Wound Healing Of Oklahoma, Inc. | Solutions and films of glycated chitosan |
| GB0028879D0 (en) * | 2000-11-27 | 2001-01-10 | Prometic Biosciences Ltd | Adsorbents and their use |
| JP2003104914A (ja) * | 2001-09-28 | 2003-04-09 | Yasuhiko Tabata | Ｄｎａ−金属−水溶性高分子複合体 |
| WO2006088473A2 (en) | 2004-04-23 | 2006-08-24 | Panduranga Rao Koritala | Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents |
| CN1308339C (zh) | 2005-02-28 | 2007-04-04 | 潘尚仁 | 99m锝标记的多胺类络合物肿瘤诊断显像剂及其制备 |
-
2007
- 2007-07-26 FR FR0756750A patent/FR2919189A1/fr not_active Withdrawn
-
2008
- 2008-07-25 MX MX2010001013A patent/MX2010001013A/es active IP Right Grant
- 2008-07-25 US US12/670,811 patent/US9023396B2/en active Active
- 2008-07-25 AU AU2008278976A patent/AU2008278976B2/en active Active
- 2008-07-25 SI SI200830730T patent/SI2175888T1/sl unknown
- 2008-07-25 WO PCT/EP2008/059825 patent/WO2009013358A2/en active Application Filing
- 2008-07-25 RS RS20120299A patent/RS52405B/en unknown
- 2008-07-25 CA CA2694582A patent/CA2694582C/en active Active
- 2008-07-25 BR BRPI0814470-2A patent/BRPI0814470B1/pt active IP Right Grant
- 2008-07-25 CN CN2008801043115A patent/CN101861171B/zh active Active
- 2008-07-25 PL PL08775355T patent/PL2175888T3/pl unknown
- 2008-07-25 JP JP2010517415A patent/JP5946241B2/ja active Active
- 2008-07-25 RU RU2010107029/15A patent/RU2481856C2/ru active
- 2008-07-25 KR KR1020107004356A patent/KR101562817B1/ko active IP Right Grant
- 2008-07-25 PT PT08775355T patent/PT2175888E/pt unknown
- 2008-07-25 ES ES08775355T patent/ES2386849T3/es active Active
- 2008-07-25 DK DK08775355.4T patent/DK2175888T3/da active
- 2008-07-25 EP EP08775355A patent/EP2175888B1/en active Active
-
2010
- 2010-01-26 IL IL203512A patent/IL203512A/en active IP Right Grant
-
2011
- 2011-04-11 HK HK11103631.6A patent/HK1149211A1/xx unknown
-
2012
- 2012-06-21 HR HRP20120526AT patent/HRP20120526T1/hr unknown
- 2012-08-07 CY CY20121100708T patent/CY1113022T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101861171A (zh) | 2010-10-13 |
| RU2010107029A (ru) | 2011-09-10 |
| FR2919189A1 (fr) | 2009-01-30 |
| IL203512A (en) | 2015-01-29 |
| MX2010001013A (es) | 2010-08-02 |
| JP2010534732A (ja) | 2010-11-11 |
| WO2009013358A2 (en) | 2009-01-29 |
| BRPI0814470B1 (pt) | 2022-03-08 |
| HK1149211A1 (en) | 2011-09-30 |
| EP2175888B1 (en) | 2012-06-13 |
| US20100254906A1 (en) | 2010-10-07 |
| AU2008278976B2 (en) | 2014-04-17 |
| SI2175888T1 (sl) | 2012-10-30 |
| AU2008278976A1 (en) | 2009-01-29 |
| WO2009013358A3 (en) | 2009-10-22 |
| US9023396B2 (en) | 2015-05-05 |
| JP5946241B2 (ja) | 2016-07-06 |
| PT2175888E (pt) | 2012-07-23 |
| BRPI0814470A2 (pt) | 2017-05-16 |
| EP2175888A2 (en) | 2010-04-21 |
| ES2386849T3 (es) | 2012-09-03 |
| RS52405B (en) | 2013-02-28 |
| RU2481856C2 (ru) | 2013-05-20 |
| DK2175888T3 (da) | 2012-07-09 |
| KR20100089059A (ko) | 2010-08-11 |
| CA2694582C (en) | 2016-02-16 |
| CY1113022T1 (el) | 2016-04-13 |
| KR101562817B1 (ko) | 2015-10-26 |
| PL2175888T3 (pl) | 2012-10-31 |
| CA2694582A1 (en) | 2009-01-29 |
| CN101861171B (zh) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120526T1 (hr) | Radiofarmaceutski pripravci koji sadrže polisaharide vezane na poliamine | |
| Zhong et al. | Polydopamine as a biocompatible multifunctional nanocarrier for combined radioisotope therapy and chemotherapy of cancer | |
| Rojas et al. | Synthesis and characterization of lanthanum phosphate nanoparticles as carriers for 223Ra and 225Ra for targeted alpha therapy | |
| Ignjatović et al. | Investigating an organ-targeting platform based on hydroxyapatite nanoparticles using a novel in situ method of radioactive 125Iodine labeling | |
| JP6526256B2 (ja) | 放射線療法用粒子と懸濁液 | |
| US20150004096A1 (en) | Tumorspecific SPECT/MR(T1), SPECT/MR(T2) and SPECT/CT contrast agents | |
| JP2010539222A5 (hr) | ||
| JP2023126209A (ja) | 安定な濃厚放射性核種錯体溶液 | |
| Massoud et al. | Characterization of polyvinylpyrrolidone (PVP) with technetium-99m and its accumulation in mice | |
| CN114748471A (zh) | 放射性标记的伊文思蓝衍生物药物的制备方法及用途 | |
| JP3048915B2 (ja) | 放射性キトサン錯体、放射性キトサン凝集粒子及び放射性キトサン錯体製造用キットと、それらの製造方法及び用途 | |
| KR100691745B1 (ko) | 테크네튬-99ｍ이 표지된 유기 게르마늄 화합물나노콜로이드, 이의 제조방법 및 용도 | |
| AU2013261858A1 (en) | Kit and method for producing a radiopharmaceutical | |
| CA2553235A1 (en) | Method and kit for the production of particles labelled with rhenium-188 | |
| Mamai et al. | Biodistribution of mesoporous carbon nanoparticles via technetium-99m radiolabelling after oral administration to mice | |
| Lakshmi Narayanan et al. | Preparation and characterization of gold nanoparticles in chitosan suspension by one-pot chemical reduction method | |
| EP3711781A1 (en) | Method for preparation of radioisotope chelating polymer nanoparticles for use in diagnostics and treatment | |
| Hawary et al. | Lactosaminated N‐succinyl‐chitosan as a liver‐targeted carrier of 99mTc in vivo for nuclear imaging and biodistribution | |
| CN110585448B (zh) | 一种用于急性肾损伤的纳米诊疗剂及其制备方法与应用 | |
| Sultana et al. | Pulmonary delivery of nanosized alendronate for decorporation of inhaled heavy metals: formulation development, characterization and gamma scintigraphic evaluation | |
| CN110935041A (zh) | 电荷翻转型聚乙烯亚胺复合金纳米颗粒及其制备和应用 | |
| Nunez et al. | Parameters optimization defined by statistical analysis for cysteine–dextran radiolabeling with technetium tricarbonyl core | |
| CN116715805B (zh) | 一种富含双膦酸基团多功能凝胶微球及其制备方法和应用 | |
| JPS5842846B2 (ja) | 肝臓および骨髄走査用テクネチウム−９９ｍ標識放射線診断剤とその製造法 | |
| Kamali et al. | Effect of pH Variation on Cross-linking of Water-soluble and Acid-soluble Chitosan with Sodium Tripolyphosphate and Gallium-67 |